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Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Parkinson’s
disease (PD). To explore the therapeutic potential of small molecules targeting the LRRK2 kinase domain, we
characterized two LRRK2 kinase inhibitors, TTT-3002 and LRRK2-IN1, for their effects against LRRK2 activity
in vitro and in Caenorhabditis elegans models of LRRK2-linked neurodegeneration. TTT-3002 and LRRK2-IN1
potently inhibited in vitro kinase activity of LRRK2 wild-type and mutant proteins, attenuated phosphorylation
of cellular LRRK2 and rescued neurotoxicity of mutant LRRK2 in transfected cells. To establish whether LRRK2
kinase inhibitors can mitigate pathogenesis caused by different mutations including G2019S and R1441C
located within and outside of the LRRK2 kinase domain, respectively, we evaluated effects of TTT-3002 and
LRRK2-IN1 against R1441C- and G2019S-induced neurodegeneration in C. elegans models. TTT-3002 and
LRRK2-IN1 rescued the behavioral deficit characteristic of dopaminergic impairment in transgenic C. elegans
expressing human R1441C- and G2019S-LRRK2. The inhibitors displayed nanomolar to low micromolar
rescue potency when administered either pre-symptomatically or post-symptomatically, indicating both pre-
vention and reversal of the dopaminergic deficit. The same treatments also led to long-lasting prevention and
rescue of neurodegeneration. In contrast, TTT-3002 and LRRK2-IN1 were ineffective against the neurodegenera-
tive phenotype in transgenic worms carrying the inhibitor-resistant A2016T mutation of LRRK2, suggesting that
they elicit neuroprotective effects in vivo by targeting LRRK2 specifically. Our findings indicate that the LRRK2
kinase activity is critical for neurodegeneration caused by R1441C and G2019S mutations, suggesting that
kinase inhibition of LRRK2 may represent a promising therapeutic strategy for PD.
INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative
disorder with the pathological hallmark of progressive loss
of dopamine (DA) neurons in affected brains. There is no
cure for PD and current therapy does not halt the underlying
degenerative process. Recent discovery of genetic causes of
PD has uncovered potentially novel targets for therapeutic
interventions that may prevent or slow down the progression
of the disease. Mutations in leucine-rich repeat kinase 2
(LRRK2) are the most frequent known cause of late-onset
familial PD (1,2). The G2019S substitution occurs within
the kinase domain of LRRK2, and it is the most common
mutation observed across a majority of populations. Patients
carrying this mutation present with clinical features indistin-
guishable from those of idiopathic PD (3). G2019S has been
found to enhance kinase activity in vitro and to promote tox-
icity in neuronal cells in culture (4,5). These findings
provide strong support for the notion that G2019S may
play a pathogenic role through a ‘gain-of-function’ mechan-
ism, prompting development of small molecule LRRK2
kinase inhibitors to counteract hyperactive LRRK2 signaling.
∗To whom correspondence should be addressed. Tel: +1 2163688925; Fax: +1 2163680494; Email: shu.chen@case.edu
# The Author 2012. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2013, Vol. 22, No. 2 328–344
doi:10.1093/hmg/dds431
Advance Access published on October 12, 2012
However, PD-associated mutations in LRRK2 occur through-
out the protein; and several of them are outside the kinase
domain, including R1441C/G and Y1699C. Although the
prevalence of R1441C/G in PD is lower than G2019S in
many populations (6,7), the reverse is also true in specific
ethnic groups such as those from the Basques and southern
Italy (8–11). Biochemical studies by different groups on
the effect of R1441C/G and Y1699C on LRRK2 kinase ac-
tivity have not provided consistent results (12). It remains to
be established whether all LRRK2 mutations initiate patho-
genesis through a gain-of-function, and whether LRRK2
kinase-specific inhibition will be effective against neurode-
generation caused by different LRRK2 mutations.
Several commercially available kinase inhibitors, originally
targeted against other kinases, have also been found to suppress
LRRK2 kinase activity in vitro (13,14). These include H-1152,
sunitinib and GW-5074. GW-5074 has also been reported to be
protective against G2019S-induced neurodegeneration in Cae-
norhabditis elegans, Drosophila and mice (14,15). However,
the low potency and poor selectivity of these compounds
toward LRRK2 raise a concern about side effects, and make it
difficult to assess whether inhibition of LRRK2 kinase alone
is sufficient to confer neuroprotection in vivo. Recently, the
first and highly selective LRRK2 inhibitor, LRRK2-IN1, was
described (16). In the present study, we have utilized a combined
pharmacological and genetic approach to examine whether
LRRK2-specific inhibition confers disease-modifying protec-
tion against neurodegeneration caused by different LRRK2
mutations. We have utilized LRRK2-IN1 and TTT-3002, a
potent inhibitor with a relatively high degree of specificity for
LRRK2, to evaluate in vivo potency, LRRK2 selectivity and
treatment time-dependent effectiveness relative to onset and
progression of behavioral symptoms and DA neurodegeneration
caused by expression of either G2019S- or R1441C-LRRK2 in
the C. elegans models of PD we have described previously (17).
Both TTT-3002 and LRRK2-IN1 potently rescued the age-
dependent dopaminergic behavioral deficit and the correspond-
ing degeneration of DA neurons in transgenic R1441C and
G2019S C. elegans. The inhibitors were effective when admi-
nistered either before or after the pathological symptoms
appeared, indicating they can also reverse dopaminergic degen-
eration. However, TTT-3002 and LRRK2-IN1 were ineffective
in treating neurodegeneration caused by dual-mutants of
LRRK2, containing a kinase inhibitor-resistant mutation
(A2016T), in addition to either the G2019S or the R1441C muta-
tions, indicating that TTT-3002 and LRRK2-IN1 are effective in
vivo by specifically targeting LRRK2. These results demon-
strate that the LRRK2-kinase activity is critical for neurodegen-
eration caused by the R1441C and G2019S mutations of
LRRK2, suggesting that kinase-targeted inhibition of LRRK2
may represent a promising strategy for therapy of PD.
RESULTS
Selective inhibition of LRRK2-dependent phosphorylation
in vitro and in intact cells
The availability of potent and selective LRRK2 inhibitors is
highly desirable to pharmacologically interrogate LRRK2
kinase activity and its role in PD, and to explore the
therapeutic potential of LRRK2 inhibition. We evaluated
several small molecules with unrelated structures (Fig. 1A)
for their inhibitory efficacy against LRRK2 in vitro. These
compounds include LRRK2-IN1, the first reported
LRRK2-selective kinase inhibitor with excellent potency and
selectivity profile (16); TTT-3002, a potent LRRK2 inhibitor
used in the present study and H-1152, a previously reported
non-selective kinase inhibitor of LRRK2 (13). These inhibitors
were tested for concentration-dependent inhibition of
LRRK2-catalyzed phosphorylation of the specific peptide sub-
strate LRRKtide, using three recombinant LRRK2 variants.
Namely, GST-tagged LRRK2 fragment encompassing resi-
dues 970–2527, corresponding to LRRK2 wild-type (WT)
and two LRRK2 mutants containing PD-causing substitutions
either within (G2019S) or outside (R1441C) the kinase
domain. All three compounds showed dose-dependent inhib-
ition of the kinase activities of the three LRRK2 variants
(Fig. 1B), displaying the same rank order of inhibitory poten-
cies against WT, R1441C and G2019S, as measured by their
half-maximal inhibitory concentrations (IC50 values)
(Table 1). LRRK2-IN1 had nanomolar inhibitory potency
with IC50 of 10 and 7.3 nM for LRRK2 WT and G2019S, re-
spectively, in good agreement with the previous report under
essentially the same assay conditions (16). The IC50 of
LRRK2-IN1 for LRRK2 R1441C is 11 nM, similar to that
for LRRK2 WT. In comparison, TTT-3002 showed the
highest potency with IC50 values of 0.7, 0.7 and 1.2 nM for
LRRK2 WT, G2019S and R1441C, respectively. H-1152 dis-
played the lowest potency with IC50 values of 140, 99 and
190 nM for LRRK2 WT, G2019S and R1441C, respectively.
These data identified TTT-3002 and LRRK2-IN1 as potent
LRRK2 kinase inhibitors with subnano- to nano-molar poten-
cies against in vitro phosphorylation by all three LRRK2 var-
iants. LRRK2-IN1 has already been shown to be quite specific
for LRRK2 according to extensive selectivity profiling against
many different protein kinases (16). The characterization of
TTT-3002, however, has previously not been presented. Al-
though an indolocarbazole, a priori assumed to be not very se-
lective, it exhibited an unexpected degree of specificity for
LRRK2 when profiled against a panel of 23 other kinases
(Supplementary Material, Table S1), many of which are nor-
mally expressed in the brain or are members of the mitogen-
activated protein kinase superfamilies to which LRRK2
belongs. More extensive analysis of TTT-3002 selectivity
against a panel of 140 kinases revealed a pattern of
concentration-dependent selectivity profile (Supplementary
Material, Table S2). At a low concentration (1 nM),
TTT-3002 only inhibited the activities of a few kinases to
.70% of the vehicle (DMSO) control. However, the selectiv-
ity of TTT-3002 decreased at higher concentrations (above 10
and 100 nM). These results suggest that TTT-3002 could have
a good LRRK2 selectivity at very low but not high concentra-
tions when used in vitro.
Notably, the nominal IC50 values of TTT-3002 for all
LRRK2 variants were below the concentrations of the respect-
ive enzyme (3–8 nM) in the in vitro assays, indicating that
TTT-3002 has a high affinity for LRRK2 and its measured
potencies were limited by the kinase concentration. Thus, its
actual inhibitory potencies and thereby the specificity for
LRRK2, would be even higher if suitable assay formats
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allowed for lower kinase concentrations. Taken together, the
results indicate LRRK2-IN1 and TTT-3002 are relatively
potent and selective LRRK2 inhibitors. Since LRRK2-IN1
and TTT-3002 differ chemically, display 10-fold different
relative potencies for LRRK2 and have off-target effects on
different non-LRRK2 kinases, their parallel use should be
helpful in the analysis of LRRK2-specific inhibition in cells.
We next examined the inhibitory effects of LRRK2-IN1 and
TTT-3002 on LRRK2-dependent phosphorylation in human
cell lines. LRRK2 is constitutively phosphorylated on serine
935 (S935), and inhibition of LRRK2 kinase activity results
in diminished S935 phosphorylation in cultured cells (13).
This allows for a robust cellular assay for small molecule inhi-
bitors using S935 phosphorylation as a readout. We probed
S935 phosphorylation of LRRK2 in human macrophage cells
and lymphocytes that express high levels of endogenous
LRRK2 (18,19), obviating the need for transfection in these
cell lines. In human THP-1 macrophage cells, LRRK2-IN1
and TTT-3002 dose-dependently inhibited endogenous S935
phosphorylation of LRRK2 (Fig. 2A). In an immortalized lym-
phoblastoid cell line derived from a PD patient carrying the
G2019S mutation, LRRK2-IN1 inhibited S935 phosphoryl-
ation of LRRK2 at concentrations of 30 nM and higher while
TTT-3002 abolished the phosphorylation at a concentration
of 3 nM (Fig. 2B). In human SH-SY5Y neuroblastoma cell
line transiently transfected with G2019S-LRRK2,
LRRK2-IN1 inhibited S935 phosphorylation of LRRK2 at
concentrations of 100 nM and higher while TTT-3002
showed prominent inhibition at concentrations 10 nM and
higher (Fig. 2C). Overall, TTT-3002 was about one order of
magnitude more potent than LRRK2-IN1 in inhibiting S935
phosphorylation of LRRK2 in cells, in general agreement
with their relative potency in inhibiting kinase activity of
recombinant LRRK2 (Fig. 1B, Table 1).
TTT-3002 and LRRK2-IN1 attenuate toxicity induced by
G2019S-LRRK2 in human SH-SY5Y neuroblastoma cell
line
Overexpression of mutant G2019S-LRRK2 causes cytotox-
icity in transfected cells, and such toxicity has been shown
to correlate with the enhanced kinase activity of the G2019S
mutation (20,21). We transfected human SH-SY5Y neuro-
blastoma cell line with WT- or G2019S-LRRK2 along with
the GFP marker. We verified co-expression of LRRK2 and
GFP in most of the transfected cells (Fig. 3A). We confirmed
that overexpression of G2019S-LRRK2 caused significantly
higher toxicity than overexpression of WT-LRRK2, as evi-
denced by reduced cell survival (Fig. 3B–D, vehicle-treated),
consistent with previous reports of a higher percentage of
apoptotic cells for G2019S overexpression (20,21). We
tested if treatment with TTT-3002 and LRRK2-IN1 could
protect against G2019S-associated cellular toxicity and
found that they significantly improved cell survival in the
G2019S transfectants (Fig. 3B–D). In direct comparison,
TTT-3002 was again more potent than LRRK2-IN1 in rescu-
ing G2019S-induced cell death. These results suggest that in-
hibition of LRRK2 protects neuronal cells from toxicity
induced by overexpression of mutant LRRK2.
Figure 1. Kinase inhibitory effects of LRRK2-IN1, TTT-3002 and H-1152 on recombinant LRRK2 and mutants in vitro. (A) Chemical structures of
LRRK2-IN1, TTT-3002 and H-1152. (B) Inhibition curves of LRRK2-IN1, TTT-3002 and H-1152 for LRRK2 WT, G2019S and R1441C. Inhibitors were
assayed in triplicate using 8 nM Invitrogen LRRK2, R1441C and G2019S separately in the presence of 100 mM ATP and 100 mM LRRKtide. The results are
presented as percentage of kinase activity relative to the vehicle control from three independent experiments performed in triplicate. Data are expressed as
mean+SEM.
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Treatment of C. elegans models of PD with LRRK2
inhibitors at different stages of neuronal impairment
We previously characterized C. elegans models of LRRK2-
linked PD in which transgenic expression of human R1441C
and G2019S LRRK2 in dopaminergic neurons caused
adult-onset and progressive behavioral deficits and neurode-
generation (17). We have devised a liquid-culture method
that allows for treatment with small molecule inhibitors for
discrete periods at different stages of worm development and
manifestation of neurodegeneration. This approach permits
us to evaluate therapeutic outcomes in terms of prevention
or rescue of PD-relevant phenotypes in C. elegans (Fig. 4A).
We sought to validate whether TTT-3002 and LRRK2-IN1
could protect against mutant LRRK2-induced dopaminergic
behavioral deficits and neurodegeneration in vivo, and to
determine if these compounds are effective both pre- and post-
symptomatically.
TTT-3002 and LRRK2-IN1 prevent and rescue mutant
LRRK2-induced dopaminergic behavioral dysfunction
The basal slowing response (also called food-sensing response)
is a well-established behavioral assay for dopamine-specific
function in C. elegans, in which well-fed worms slow down
their locomotive activity after encountering bacterial food
(22). As we described previously (17), transgenic expression
of R1441C- and G2019S-LRRK2 causes dopamine-specific
locomotive dysfunction in C. elegans manifested as adult-onset
and progressive loss of the basal slowing response beginning on
adult Day 2, with a complete loss of the dopamine-dependent
behavioral response on adult Day 4. To test whether inhibition
of LRRK2 kinase activity could protect against dopaminergic
behavioral dysfunction caused by PD-linked mutations, we
treated R1441C- and G2019S-LRRK2 transgenic C. elegans
with TTT-3002 and LRRK2-IN1 at different developmental
stages and assayed the behavioral response on adult Day 4.
We first incubated worms with the chemicals during the first
(L1) to the last (L4) larval stage. As shown in Figure 4B, the
vehicle-treated R1441C and G2019S worms were defective in
basal slowing response (i.e., low % slowing). However, treat-
ment with TTT-3002 and LRRK2-IN1 restored the basal
slowing response in both R1441C and G2019S transgenic
LRRK2 worms in a dose-dependent manner. The control
worms expressing the GFP marker in DA neurons showed
normal behavior that was unaltered by the treatments with
either compound. The EC50 (half maximal effective concentra-
tion) values for TTT-3002 were 0.02 and 0.22 mM for preventing
the dopaminergic behavioral deficit in transgenic worms
expressing R1441C and G2019S, respectively (Table 2). The
corresponding EC50 values for behavioral rescue by
LRRK2-IN1 were 0.10 and 0.51 mM in transgenic worms
expressing R1441C and G2019S, respectively. In contrast,
H-1152 was ineffective even at concentrations as high as
10 mM, and showed only a partial effect at 100 mM in transgenic
R1441C worms (Supplementary Material, Fig. S1). Therefore,
TTT-3002 and LRRK2-IN1 are highly effective in early preven-
tion of dopaminergic behavioral impairment caused by R1441C
and G2019S expression in C. elegans DA neurons.
We examined LRRK2 expression levels in transgenic
worms expressing G2019S- and R1441C-LRRK2. We were
unable to detect LRRK2 proteins in total lysates of LRRK2
transgenic worms by western blotting, likely due to the expres-
sion of LRRK2 constructs only in dopaminergic neurons
(eight per animal). Following affinity pull-down of LRRK2
from large populations of worms, we confirmed the expression
of LRRK2 proteins in transgenic worms expressing R1441C
and G2019S before and after treatment with inhibitors (Sup-
plementary Material, Fig. S2). To accurately determine
LRRK2 expression in individual worms, we examined
LRRK2 mRNA expression in single worms using quantitative
real-time PCR (qPCR). We verified amplification of LRRK2
transcripts in R1441C and G2019S transgenic worms from
RNA extracted from single animals using an LRRK2-specific
primer. Data from qPCR analysis revealed a higher LRRK2
mRNA level in transgenic R1441C worms relative to trans-
genic G2019S worms (Supplementary Material, Fig. S2).
We next treated worms from L4 (adult Day 0) to adult Day 2
when the initial behavioral symptoms began to develop in trans-
genic worms expressing mutant LRRK2. Again, TTT-3002 and
LRRK2-IN1 were able to prevent the dopaminergic behavioral
deficit caused by mutant LRRK2 (Fig. 4C). Compared with the
L1-L4 treatment, TTT-3002 maintained similar potency
(EC50 ¼ 0.03 mM) while LRRK2-IN1 showed a reduction in
potency (EC50 ¼ 1.33 mM) in behavioral rescue of R1441C
transgenic worms (Table 2). For G2019S transgenic worms,
both chemicals exhibited considerably reduced potency when
compared with the L1–L4 treatment, with EC50 values of
0.90 mM for TTT-3002 and 2.83 mM for LRRK2-IN1.
Finally, when treatment occurred from adult Day 2 to Day 3,
during which severe behavioral phenotype already was manifest
in transgenic worms expressing R1441C and G2019S, both
TTT-3002 and LRRK2-IN1 also showed dose-dependent
rescue of the behavioral deficit in these worms (Fig. 4D). EC50
values were 0.04 mM for TTT-3002 and 2.22 mM for
LRRK2-IN1 in behavioral rescue of R1441C transgenic worms,
and 0.94 mM for TTT-3002 and 6.80 mM for LRRK2-IN1 in treat-
ing G2019S transgenic worms (Table 2). Taken together, our
results demonstrate that TTT-3002 and LRRK2-IN1 potently
prevent and rescue the dopamine-dependent behavioral pheno-
type induced by LRRK2 mutants in C. elegans during pre- and
post-symptomatic periods, respectively.
TTT-3002 and LRRK2-IN1 arrest mutant
LRRK2-induced neurodegeneration in vivo
We evaluated whether rescue of the dopamine-dependent
behavioral phenotype by TTT-3002 and LRRK2-IN1 corre-
lated as expected with protection against dopaminergic
Table 1. IC50 values for LRRK2-IN1, TTT-3002 and H-1152 toward WT-,
R1441C- and G2019S-LRRK2a
IC50 (nM)
WT R1441C G2019S
LRRK2-IN1 10.0 11.0 7.3
TTT-3002 0.70 1.2 0.70
H-1152 140 190 99
aDerived from inhibition curves in Figure 1.
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Figure 2. Effect of LRRK2-IN1 and TTT-3002 on S935 phosphorylation of LRRK2 in human cell lines. LRRK2-IN1 and TTT-3002 inhibited S935 phosphor-
ylation of LRRK2 in human THP-1 macrophages (A), human lymphoblastoid cell line derived from a PD patient carrying the G2019S mutation (B) and human
SH-SY5Y neuroblastoma cell line transfected with G2019S-LRRK2 plasmid (C). The inhibitory effects of LRRK2-IN1 and TTT-3002 on S935 phosphorylation
of LRRK2 were attenuated in cells transfected with G2019S/A2016T plasmid (D). All cell lines were treated with varying concentrations of LRRK2-IN1 and
TTT-3002 for 1.5 h. Cell lysates were subjected to immunoblotting for detection of S935 phosphorylation (pS935 LRRK2) using a rabbit mAb UDD2 against
phospho-serine 935 LRRK2, and for detection of total LRRK2 using a mouse mAb against LRRK2 amino acids 970–2527. The position of the 250 kDa mo-
lecular weight marker was indicated on each blot. The bar graphs represent percent pS935 LRRK2 normalized to total LRRK2 in untreated and inhibitor-treated
samples, using band intensities determined from scanned blot images with the ImageJ software. The results were obtained from three independent experiments
and values are expressed as mean+SEM.
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neurodegeneration in transgenic R1441C and G2019S worms.
We conducted treatment regimens analogous to those used for
behavioral rescue (treatments during L1–L4, L4–Day 2 and
Day 2–Day 3), as well as treatment during adult Day 5 to
Day 7 when there was already marked neuronal loss in
untreated animals. Following treatments with TTT-3002 and
LRRK2-IN1, we monitored the surviving dopamine (DA)
neurons in the head (CEP and ADE neurons according to no-
menclature for C. elegans) in aged worms on adult Day 9. As
shown for the L1–L4 treatment period (Fig. 5A), only about
Figure 3. TTT-3002 and LRRK2-IN1 attenuate cytotoxicity induced by overexpression of G2019S-LRRK2 and WT-LRRK2 in SH-SY5Y cells. SH-SY5Y cells
were transiently transfected with WT-LRRK2, G2019S-LRRK2 and empty vector along with GFP at 15:1 ratio. (A) Images of GFP, LRRK2 immunostaining
(Anti-LRRK2) and merges were made from SH-SY5Y cells transfected with empty vector, WT-LRRK2 and G2019S-LRRK2 plasmids. Cells were stained 48 h
post-transfection with LRRK2 rabbit mAb UDD3 and Alexa Fluor 488 labeled goat anti-rabbit antibody. Cell images were taken at ×40 magnification. There
was little LRRK2 staining in the empty vector control group. The cells positive for LRRK2 staining were analyzed for their overlap with co-expressed GFP
signals in WT-LRRK2 and G2019S-LRRK2 transfection groups using 30 randomly imaged fields (n ¼ 120–150 cells for each group), as shown in the bar
graph. The results were obtained from three independent experiments and values are expressed as mean+SEM. n.d., not detected. (B) GFP images of cells
treated with vehicle, TTT-3002 and LRRK2-IN1. At 48 h post-transfection, cell images were taken at 30 randomly selected fields at ×20 magnification per
treatment group by using GFP channel. (C) Merged images of GFP and Hoechst 3332 staining. At 48 h post-transfection, cells were treated with Hoechst
3332 and images were taken at 30 randomly selected fields at ×20 magnification per group by using both GFP channel and DAPI channel. The GFP image
and DAPI image were superimposed for identifying the viable GFP positive cells. (D) Quantitative analysis of GFP positive and viable cells. WT-LRRK2
and G2019S-LRRK2 transfection caused a reduction in the number of GFP positive (left panel) and percentage (right panel) of viable GFP positive cells
when compared with empty vector (vehicle controls). Both TTT-3002 and LRRK2-IN1 treatments significantly increased the number of GFP positive cells
(left panel) and percentage of viable GFP positive cells (right panel) in WT-LRRK2 and G2019S-LRRK2 transfectants. TTT-3002 and LRRK2-IN1 did not
affect number of GFP positive cells transfected with empty vector. The results were obtained from three independent experiments and values are expressed
as mean+SEM. ∗P , 0.05 by one-way ANOVA, inhibitor-treated vs. vehicle-treated samples in WT-LRRK2 and G2019S-LRRK2 transfectants.
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Figure 4. Treatment with TTT-3002 and LRRK2-IN1 during different life stages prevents or rescues behavioral deficit in transgenic R1441C and G2019S
worms. (A) Treatment regimens of C. elegans with small molecule inhibitors. For assessing the ‘preventive’ effect of LRRK2 inhibitors against C. elegans
behavioral deficits and DA neuronal loss, R1441C and G2019S transgenic C. elegans were treated with TTT-3002 and LRRK2-IN1 in liquid culture over
the periods L1–L4 and L4 to adult Day 2, respectively. These are early stages of life span prior to overt LRRK2-linked behavioral abnormality and DA neuronal
loss. For assessing the ‘rescue’ effect of LRRK2 inhibitors against C. elegans behavior deficit and DA neuronal loss, R1441C and G2019S transgenic C. elegans
were treated with TTT-3002 and LRRK2-IN1 in liquid culture for the periods of adult Day 2 to Day 3, and adult Day 5 to Day 7, respectively. Both transgenic
R1441C and G2019S lines manifested severe behavioral impairment since adult Day 2 and progressive DA neurodegeneration starting approximately at adult
Day 5. (B) Treatment during L1–L4: dose–response curves for TTT-3002 and LRRK2-IN-1 in preventing R1441C and G2019S transgenic C. elegans behavior
abnormality. The behavioral response for GFP control worms (dotted lines) was not altered by either TTT-3002 or LRRK2-IN1. (C) Treatment during L4 to adult
Day 2: shown are dose–response curves for TTT-3002 and LRRK2-IN-1 in rescuing behavior deficit of R1441C and G2019S transgenic C. elegans. (D) Treat-
ment during adult Day 2 to Day 3: shown are dose–response curves for TTT-3002 and LRRK2-IN1 in reversing the behavioral deficit of R1441C and G2019S
transgenic C. elegans. Results were obtained from three independent experiments, each with 10–15 worms per genotype for a given compound concentration.
Values are expressed as mean+SEM.
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40% of DA neurons remained on adult Day 9 in transgenic
worms expressing either R1441C or G2019S that were
treated with vehicle only, while about 80% of DA neurons sur-
vived in the control worms expressing the GFP marker. Treat-
ment with TTT-3002 and LRRK2-IN1 at minimal dosages
required for full behavioral rescue resulted in significant im-
provement of neuronal survival in transgenic R1441C and
G2019S worms. Consistent with the findings from behavioral
rescue, transgenic worms expressing R1441C were more sen-
sitive to LRRK2 inhibitors, requiring lower dosages for arrest-
ing neurodegeneration than those expressing G2019S.
Likewise, treatments during L4 to Day 2 (Fig. 5B) and Day
2 to Day 3 (Fig. 5C) with TTT-3002 and LRRK2-IN1, each
at a concentrations required for full behavioral rescue, resulted
in significant protection against neurodegeneration in trans-
genic R1441C and G2019S worms. We observed similar find-
ings even for the later treatment during Day 5 to Day 7, albeit
with higher concentrations of inhibitors than used in younger
animals (Fig. 5D). Taken together, our data indicate that treat-
ment of TTT-3002 and LRRK2-IN1 during both pre- and post-
symptomatic stages significantly protect DA neurons against
neurodegeneration caused by R1441C and G2019S.
TTT-3002 and LRRK2-IN1 specifically target LRRK2
in vivo
To validate that the therapeutic outcomes of TTT-3002 and
LRRK2-IN1 against dopaminergic behavioral deficit and neu-
rodegeneration in transgenic worms expressing R1441C- and
G2019S-LRRK2 are due to specific inhibition of the LRRK2
kinase activity, we took advantage of a rationally designed
inhibitor-resistant A2016T mutation of LRRK2. As shown
previously, the A2016 residue in the kinase domain of
LRRK2 is required for its sensitivity to LRRK2 kinase inhibi-
tors (13), and the A2016T mutation renders LRRK2 wild-type
and G2019S resistant to LRRK2-IN1 in vitro (16). We con-
firmed that SH-SY5Y cells overexpressing G2019S/A2016T
were more resistant to inhibition of S935 LRRK2 phosphoryl-
ation by LRRK2-IN1 and TTT-3002 (Fig. 2D) when compared
with those overexpressing G2019S (Fig. 2C). However, the
effects of the A2016T mutation on LRRK2 activity and its
sensitivity to inhibitors have not been examined in vivo.
Therefore, we constructed transgenic C. elegans lines expres-
sing R1441C/A2016T- or G2019S/A2016T-LRRK2 double
mutants in DA neurons. As shown in Figure 6, transgenic
R1441C/A2016T- or G2019S/A2016T-LRRK2 worms mani-
fested the same phenotype of dopaminergic behavioral
deficit and neurodegeneration as transgenic single mutant
R1441C- and G2019S-LRRK2 lines (vehicle treatment), indi-
cating that the A2016T mutation does not alter the pathogen-
icity of R1441C- and G2019S-LRRK2 in vivo. This is
consistent with the in vitro finding that A2016T mutation
does not affect the intrinsic kinase activity of LRRK2 (13).
When treated with TTT-3002 and LRRK2-IN1, transgenic
double mutant R1441C/A2016T and G2019S/A2016T
worms were much more resistant to the rescuing effects on be-
havioral defects by both inhibitors than their respective single-
mutant R1441C and G2019S worms (Fig. 6A). When treated
with TTT-3002 and LRRK2-IN1 at concentrations that fully
rescue the behavioral deficits in transgenic R1441C and
G2019S worms but with no or partial effects on the
R1441C/A2016T and G2019S/A2016 worms, both inhibitors
significantly enhanced the survival of DA neurons in transgen-
ic worms expressing R1441C and G2019S, but failed to rescue
neurodegeneration in transgenic R1441C/A2016T and
G2019S/A2016T worms (Fig. 6B). Hence, the A2016T muta-
tion desensitizes LRRK2 in response to kinase inhibitors.
These results fully establish transgenic R1441C/A2016T and
G2019S/A2016T worms as useful in vivo models for validat-
ing direct targeting of LRRK2 by small molecule inhibitors.
Our findings suggest that TTT-3002 and LRRK2-IN1 arrest
the PD-relevant pathogenesis by specifically inhibiting the
kinase activity of R1441C and G2019S in vivo.
TTT-3002 and LRRK2-IN1 have no effect on
neurodegeneration induced by exogenous neurotoxin or
other factors
We also examined whether TTT-3002 and LRRK2-IN1 had
any protective effects on other worm models of neurodegen-
eration unrelated to LRRK2. We exposed worms expressing
GFP marker in DA neurons to the neurotoxin
6-hydroxy-dopamine (6-OHDA) which is selectively trans-
ported into DA neurons of both mammals and worms and
induces degeneration (23). We incubated the GFP worms
with vehicle or LRRK2 inhibitors from L1 until L3, exposed
L3 worms to 6-OHDA for 1 h and re-incubated with vehicle
or LRRK2 inhibitors for an additional 24 h. Then DA
neurons were monitored at 24, 48 and 72 h post 6-OHDA ex-
posure. As shown in Figure 7A, 6-OHDA caused progressive
loss of DA neurons 48 and 72 h post exposure, a reproducible
phenotype, as described previously (23). We also considered
whether TTT-3002 and LRRK2-IN1 inhibit LRK-1 in vivo,
the C. elegans homolog of mammalian LRRK2. As reported
previously, loss of LRK-1 in worms render the DA neurons
hypersensitive to 6-OHDA (24). We treated lrk-1 deletion
worms in the absence or presence of TTT-3002 (0.5 mM)
and LRRK2-IN1 (1 mM), and assayed vulnerability of DA
neurons to 6-OHDA. As shown in Supplementary Material,
Figure S3, we confirmed that the lrk-1 null worms were
more vulnerable to neurodegeneration caused by 6-OHDA.
However, TTT-3002 and LRRK2-IN1 did not seem to alter
6-OHDA induced toxicity in either the control GFP or lrk-1
mutant animals when compared with the vehicle control.
Therefore, it is likely that these two inhibitors did not affect
Table 2. Quantification of in vivo EC50 values in different treatment regimens
for TTT-3002 and LRRK2-IN1 in rescuing the behavioral deficit displayed by
R1441C- and G2019S-LRRK2 transgenic C. elegansa
Treatment Inhibitor R1441C (EC50, mM) G2019S (EC50, mM)
L1–L4 LRRK2-IN1 0.10 0.51
TTT-3002 0.02 0.22
L4–Day 2 LRRK2-IN1 1.33 2.83
TTT-3002 0.03 0.90
Day 2–Day 3 LRRK2-IN1 2.22 6.80
TTT-3002 0.04 0.94
aDerived from Figure 4.
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endogenous LRK-1, at least in the concentrations used for our
study. Taken together, TTT-3002 and LRRK2-IN1 had no
effect on neurodegeneration in this model.
We next evaluated neurodegeneration induced by overpro-
duction of DA in transgenic worms overexpressing CAT-2
(the C. elegans homolog of tyrosine hydroxylase) in DA
neurons. The transgenic CAT-2 overexpression line exhibited
marked neurodegeneration on adult Day 4 (Fig. 7B), consist-
ent with previous results (17). Treatment with TTT-3002
and LRRK2-IN1 showed no protective effect on these worms.
We also treated the GFP control worms with inhibitors
during L1–L4 and monitored DA neurons in old animals on
adult Day 9 (Supplementary Material, Fig. S4). The GFP
worms showed about 20% loss of DA neurons on adult Day
9 due to aging in vehicle-treated controls. TTT-3002 and
LRRK2-IN1 had no protective effect on DA neuron survival,
indicating that these LRRK2 inhibitors do not affect DA
neuron integrity in normal animals. We also observed that
TTT-3002 and LRRK2-IN1 had no effect on lifespan in
either worms expressing GFP marker alone or
G2019S-LRRK2 (Supplementary Material, Fig. S5), consist-
ent with the fact that DA neurons per se in worms are dispens-
able for organism survival. Since changes in signaling through
post-synaptic dopamine receptors DOP-1 and DOP-3
expressed in other neurons can also affect the basal slowing
response of the worms (25), we tested whether rescuing
effects of TTT-3002 and LRRK2-IN1 on R1441C-induced be-
havioral deficits depend on DOP-1 or DOP-3. We generated
R1441C transgenic worms in the dop-1 null background, and
assayed effects of TTT-3002 and LRRK2-IN1 in this model.
As shown in Supplementary Material, Figure S6, loss of
DOP-1 did not change the neurotoxicity of R1441C, and the
LRRK2 inhibitors remained effective in rescuing the behavior-
al deficits in the dop-1/R1441C worms. In addition, the
LRRK2 inhibitors did not alter the basal slowing response in
either dop-1 or dop-3 mutant worms when compared with
the vehicle controls. Therefore, it seemed unlikely that TTT-
3002 and LRRK2-IN1 rescued R1441C-induced behavioral
deficits through a DOP-1/DOP-3-dependent mechanism.
Finally, the C. elegans lines expressing R1441C, G2019S,
R1441C/A2016T and G2019S/A2016T all displayed promin-
ent dopaminergic behavioral deficits that can be symptomatic-
ally rescued with exogenous L-DOPA (Supplementary
Material, Fig. S7; and data not shown). Hence, they are
useful models for studying LRRK2-relevant pathogenesis
and for screening small molecules with neuroprotective
effects. Taken together, these results indicate that TTT-3002
and LRRK2-IN1 do not affect DA neurodegeneration
induced by factors other than LRRK2, which is consistent
with the interpretation that TTT-3002 and LRRK2-IN1 specif-
ically target LRRK2 kinase activity to confer neuroprotection.
DISCUSSION
In the present study, we take advantage of potent and selective
LRRK2 inhibitors to interrogate LRRK2 kinase activity and
elucidate its role in dopaminergic neurodegeneration caused
by different LRRK2 mutations using C. elegans models. We
have been able to pharmacologically rescue the pathological
phenotype manifested by the expression of mutant LRRK2
G2019S and R1441C in vivo. Although it is still being
debated whether and how mutations outside kinase domain
such as R1441C affect the intrinsic LRRK2 kinase activity
(12), the results from our study are consistent with a toxic
‘gain of function’ mechanism for G2019S- and
R1441C-linked PD, likely due to aberrant kinase activity
that can be suppressed by select small molecule inhibitors.
We have shown that both TTT-3002 and LRRK2-IN1 po-
tently inhibit in vitro kinase activities of LRRK2 wild-type,
R1441C and G2019S at nanomolar concentrations, and have
confirmed their ability to inhibit endogenous LRRK2 in a cel-
lular environment based on detection of S935 phosphorylation
of LRRK2 at potencies that reflect those determined in the en-
zymatic assays. The inhibitory effects of TTT-3002 and
LRRK2-IN1 on LRRK2 kinase activity also correlated well
with their protective effect on neurotoxicity induced by trans-
fected G2019S-LRRK2 in SH-SY5Y neuroblastoma cells.
Furthermore, we have evaluated the effects of both inhibitors
on dopaminergic behavioral and neurodegenerative pheno-
types in our previously established transgenic C. elegans
lines overexpressing G2019S- and R1441C-LRRK2.
TTT-3002 and LRRK2-IN1 prevented and rescued G2019S-
and R1441C-linked behavioral abnormality when treated
during both pre- and post-symptomatic stages, and arrested
DA neurodegeneration in aged G2019S- and
R1441C-LRRK2 transgenic C. elegans. In all of these
studies, TTT-3002 was typically about 10-fold more potent
than LRRK2-IN1. Various control experiments indicated that
the rescue of behavior abnormality and DA neurodegeneration
in R1441C and G2019S transgenic lines are not the result of
non-specific or off-target effects of either inhibitor: (i)
TTT-3002 and LRRK2-IN1 were much less effective in rescu-
ing phenotypes of inhibitor-resistant R1441C/A2016T and
G2019S/A2016T C. elegans lines, suggesting that both inhibi-
tors directly target LRRK2. Like the R1441C and G2019S
transgenic worms, R1441C/A2016T and G2019S/A2016T dis-
played dopaminergic defects that could be rescued by treat-
ment with exogenous L-DOPA. Therefore, the R1441C/
A2016T and G2019S/A2016T models are highly relevant in
testing the specificity of LRRK2 inhibitors and (ii) both inhi-
bitors had no effect on DA neuron survival of wild-type
animals expressing GFP marker alone, or on neurodegenera-
tion caused by factors other than mutant LRRK2. These
results suggest that kinase activity is critical for both
R1441C- and G2019S-linked pathogenesis in C. elegans,
and support the notion that pharmacological inhibition of
LRRK2 may have disease-modifying effects on PD associated
with aberrant LRRK2-dependent signaling. TTT-3002 is par-
ticularly promising for further evaluation in mammalian
models of PD as it can be dosed orally in mice to sustain
brain levels of 300–400 nM over a period of several months
without notable toxicity or any other detectable adverse
effects on behavior and learning and memory (H. Roder, un-
published data).
Our liquid-culture treatment regimens developed in the
present study have allowed for sensitive and quantitative as-
sessment of in vivo efficacies and kinetics of rescue by
LRRK2 inhibitors at different stages of development and
manifestation of neurodegenerative phenotypes in C. elegans
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models. Consequently, we are able to make several observa-
tions that reveal interesting differences in efficacy and
pharmacodynamics of different LRRK2 inhibitors, and in sen-
sitivity of transgenic C. elegans carrying different LRRK2
mutations toward compound treatments. First, the potencies
of both TTT-3002 and LRRK2-IN1 in the C. elegans models
(Fig. 4 and Table 2) were lower than in the in vitro enzyme
assays (Fig. 1 and Table 1) or in the cellular model systems
(Figs 2 and 3). It is possible that the availability of the inhibi-
tors to its target (mutant LRRK2) expressed in DA neurons of
C. elegans is limited by tissue penetration and other regulatory
or metabolic mechanisms, which also affect whole-animal
Figure 5. Treatment with TTT-3002 and LRRK2-IN-1 arrests neurodegeneration in transgenic R1441C and G2019S worms. Transgenic C. elegans lines were
treated with vehicle, TTT-3002 and LRRK2-IN-1 during L1–L4 stage (A), L4 to adult Day 2 (B), adult Day 2 to adult Day 3 (C) and adult Day 5 to adult Day 7
(D). When left untreated (vehicle control) and examined on adult Day 9, only 40% of ADE/CEP head DA neurons remained in both R1441C and G2019S
transgenic C. elegans, while 80% of ADE/CEP head DA neurons were present in GFP control C. elegans. (A) Representative fluorescence images taken
on adult Day 9 following treatments in liquid culture during L1–L4 stage with vehicle control, LRRK2-IN1 and TTT-3002 of transgenic C. elegans expressing
GFP marker only or additionally R1441C- and G2019S-LRRK2 in DA neurons (left panel), and quantitation of DA neurons in the head region monitored at L4
stage (adult Day 0) and on adult Day 9 (right panel). (B) Representative fluorescence images taken on adult Day 9 following treatments in liquid culture from L4
to adult Day 2 with vehicle control, LRRK2-IN1 and TTT-3002 of transgenic C. elegans expressing GFP marker only or additionally R1441C- and
G2019S-LRRK2 in DA neurons (left panel), and quantitation of DA neurons in the head region monitored at L4 stage (adult Day 0) and on adult Day 9
(right panel). (C) Representative fluorescence images taken on adult Day 9 following treatments in liquid culture from adult Day 2 to Day 3 with vehicle
control, LRRK2-IN1 and TTT-3002 of transgenic C. elegans expressing GFP marker only or additionally R1441C- and G2019S-LRRK2 in DA neurons
(left panel), and quantitation of DA neurons in the head region monitored at L4 stage (adult Day 0) and on adult Day 9 (right panel). (D) Representative fluor-
escence images taken on adult Day 9 following treatments in liquid culture from adult Day 5 to Day 7 with vehicle control, LRRK2-IN1 and TTT-3002 of
transgenic C. elegans expressing GFP marker only or additionally R1441C- and G2019S-LRRK2 in DA neurons (left panel), and quantitation of DA
neurons in the head region monitored on adult Day 5 and on adult Day 9 (right panel). In all the treatment regimens, both TTT-3002 and LRRK2-IN1 signifi-
cantly enhanced the percentage of surviving DA neurons assayed on adult Day 9. DA neurons in the head region were monitored at the L4 stage, on adult Day 5
or adult Day 9 using a fluorescence microscope. Results were obtained from three independent experiments, each with about 30 worms per genotype for a given
compound concentration. Values are expressed as mean+SEM. ∗∗∗P , 0.01 and ∗P, 0.05 by one-way ANOVA.
Figure 6. Transgenic worms expressing R1441C/A2016T- and G2019S/A2016T-LRRK2 exhibit dopaminergic behavioral deficit and neurodegeneration but are
resistant to treatment with LRRK2 inhibitors. When left untreated, R1441C/A2016T- and G2019S/A2016T-LRRK2 transgenic C. elegans manifested similar
age-dependent dopaminergic behavioral deficit (A) and neurodegeneration (B) as the R1441C- and G2019S-LRRK2 transgenic lines. (A) Transgenic C.
elegans lines expressing R1441C, G2019S, R1441C/A2016T and G2019S/A2016T in DA neurons were treated during L1–L4 in liquid culture with vehicle
and different concentrations of TTT-3002 and LRRK2-IN1. Transgenic C. elegans lines expressing R1441C/A2016T and G2019S/A2016T were less sensitive
to behavioral rescue by TTT-3002 and LRRK2-IN1 than those expressing R1441C and G2019S. (B) TTT-3002 at 0.5 and 1 mM, and LRRK2-IN1 at 1 mM sig-
nificantly enhanced DA neuron survival on adult Day 9 in R1441C- and G2019S-LRRK2 transgenic C. elegans lines, respectively. Little or no improvement in
DA neuron survival was observed for either of the R1441C/A2016T- and G2019S/A2016T-LRRK2 lines treated with TTT-3002 and LRRL2-IN1. DA neurons in
the head region were monitored at the L4 stage or on adult Day 9 using a fluorescence microscope. Results were obtained from three independent experiments,
each with about 30 worms per genotype for a given compound concentration. Values are expressed as mean+SEM. ∗∗∗P , 0.01, and n.s. (not significant) by
one-way ANOVA.
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pharmacology in mammals. Second, TTT-3002 was not only
more potent but also had a remarkably steeper dose–response
curve than LRRK2-IN1 across the treatment regimens and in
both R1441C and G2019S transgenic C. elegans lines
(Fig. 4 and Table 2). It is also noteworthy that increasing con-
centrations are required the later the treatment is administered,
more so for the less potent LRRK2-IN1 than for TTT-3002.
These results correlate with the better in vitro potency of
TTT-3002 but also suggest higher affinity of TTT-3002 for
LRRK2 proteins than that of LRRK2-IN1. Unexpectedly,
transgenic worms expressing R1441C were dramatically
more sensitive to either inhibitor in rescue of behavior
deficit (Fig. 4) and neurodegeneration (Fig. 5) than those
expressing G2019S, with EC50 values differing across treat-
ment regimens by 20- to 100-fold for TTT-3002 and 2- to
5-fold for LRRK2-IN1, respectively (Table 2). This is intri-
guing considering that in vitro kinase assays revealed similar
potency of inhibition toward R14411C- and G2019S-LRRK2
by either TTT-3002 or LRRK2-IN1 (Table 1). Conceivably,
there could be several explanations for the observed differ-
ences in the response of R1441C- and G2019S transgenic
worms to treatment by LRRK2 inhibitors. Considering the
high affinity of TTT-3002 and LRRK2-IN1 for LRRK2,
their apparent EC50 values would become dependent on
LRRK2 concentration at levels approaching or exceeding
the dissociation constant (Ki). Accordingly, the two inhibi-
tors, especially the more potent TTT-3002, would display dif-
ferent apparent potencies that correlate with the expression
levels of R1441C- and G2019S-LRRK2 proteins in the re-
spective transgenic C. elegans models. However, we consider
this scenario less likely since relative LRRK2 mRNA levels
in transgenic R1441C and G2019S worms do not correlate
directly with their sensitivities to the inhibitors (Supplemen-
tary Material, Fig. S2). Another possibility is that binding
of the different LRRK2 inhibitors to the R1441C- or
G2019S-LRRK2 proteins may induce different conformation-
al changes in the mutant proteins and differentially affect
downstream signaling. Consistent with the concept of differ-
ential conformation in LRRK2 mutants, it was previously
reported that the R1441C mutation alters the folding proper-
ties of the GTPase domain of LRRK2 and also lowers the
thermodynamic stability in vitro (26). Adding to the com-
plexity of the interpretation is the observation that LRRK2
proteins can undergo dimerization and association with mem-
brane structures and likely with other proteins (27–32),
which may modify local concentrations of LRRK2 proteins.
However, it is unknown whether these interactions would
be impacted differentially by the different LRRK2 mutations
and LRRK2 inhibitors. Finally, different degrees of inhibition
may be required to rescue the equivalent phenotype caused
by the R1441C and G2019S mutations. Further research is
clearly required to resolve these issues. Nevertheless, our
pharmacological approach that integrates different treatment
regimens and sensitive phenotypic assays, combined with
genetic models with an engineered mutation affecting drug
sensitivity should be generally applicable to screening and
characterization of other bioactive compounds in C. elegans
models.
In summary, our study has provided strong evidence that
specific inhibition of LRRK2 kinase activity can protect DA
neurons from degeneration induced by pathogenic LRRK2
mutations. Our findings on the anti-neurodegenerative
Figure 7. TTT-3002 and LRRK2-IN1 have no effect on neurodegeneration induced by exposure to 6-OHDA or overproduction of DA. (A) GFP worms were
treated with different concentrations of TTT-3002 and LRRK2-IN-1 from L1 to L3, exposed to 6-OHDA for 1 h, and re-treated with TTT-3002 and LRRK2-IN1
for another 24 h. The DA neurons were monitored from 0 h (L3), 24, 48 and 72 h after 6-OHDA exposure. No significant improvement of DA neuron survival in
TTT-3002 and LRRK2-IN1 treatment groups were observed. (B) The CAT-2 overexpressing C. elegans were treated with different concentrations of TTT-3002
and LRRK2-IN-1 from L1–L4. CAT-2 overexpression generates excessive dopamine and leads to DA neuron degeneration in C. elegans on adult Day 4. The
DA neurons were monitored at L4 stage and on adult Day 4. No change in DA neuron survival was observed between vehicle controls and groups treated with
TTT-3002 or LRRK2-IN1.
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potential of LRRK2-selective inhibitors should encourage
further validation of this therapeutic strategy in mammalian
models, and ultimately clinical evaluation in PD.
MATERIALS AND METHODS
Chemicals
Small molecule kinase inhibitors used were LRRK2-IN1 (16),
obtained from Michael J. Fox Foundation for Parkinson’s Re-
search; TTT-3002, supplied by TauTaTis, Inc. (San Diego,
CA, USA); and H-1152, purchased from Calbiochem. All
other chemicals were from Sigma unless otherwise indicated.
Determination of in vitro IC50 and kinase selectivity
We used the ADP-Glo kinase assay kit (Promega) to deter-
mine the IC50 values for LRRK2 inhibitors. All inhibitors
were stored at 2808C as 10 mM stocks dissolved in dimethyl
sulfoxide (DMSO). Prior to each assay, they were diluted with
Kinase Buffer A (Invitrogen), with the final DMSO concentra-
tion kept at 1% for all samples. Other assay components were
also prepared in Kinase Buffer A. Assays were conducted in
triplicate in separate wells of a Corning 384-well low-volume
white plate in a final volume of 5 ml, containing 8 nM recom-
binant LRRK2 wild-type [GST-LRRK2 (970–2547), Invitro-
gen], 100 mM LRRKtide (LRRK2 peptide substrate,
Invitrogen), and varying concentrations of inhibitors
(LRRK2-IN1, TTT-3002 and H-1152). The vehicle control
contained 1% DMSO in place of inhibitor. The reactions
were initiated with 100 mM ATP (Promega), and incubated
at room temperature (228C) for 1 h. The reactions were
quenched and detection of the ATP turnover was accom-
plished by using the ADP-Glo system according to the manu-
facturer’s instructions (Promega). Briefly, 5 ml of ADP-Glo
reagent was added to each well and incubated for 40 min.
Then, 10 ml of kinase detection substrate was added to each
well and incubation was continued for an additional 30 min
at room temperature (228C). Luminescence was measured
with a TECAN Genios plate reader. Analogous reactions
were conducted with recombinant G2019S-LRRK2 or
R1441C-LRRK2 (Invitrogen).
Independent assays for inhibitory potency of LRRK2-IN1
for LRRK2 wild-type and G2019S, but not R1441C, as well
as selectivity profiling of LRRK2-IN1 against many different
kinases were reported previously (16). Kinase selectivity pro-
filing for TTT-3002 was described in the Supplemental
Experimental Procedures.
Detection of S935 phosphorylation of cellular LRRK2
Immortalized primary human lymphoblastoid cells propagated
from leukocytes from one PD patient carrying the G2019S
mutation were obtained from the Coriell Institute for
Medical Research (Camden, NJ). Human lymphoblastoid
cells were maintained in RPMI 1640 with 10% FBS, 2 mM
glutamine, 1× penicillin/streptomycin solution (Invitrogen)
at a cell density of 1 × 106 cells per milliliter. Two million
cells were plated into each well of a six-well plate, with
5 ml medium per well. Various working solutions of
LRRK2-IN1 and TTT-3002 (at 1000 times the final concentra-
tions) were made by serial dilutions with water from stock
solutions made in DMSO and adjusting the DMSO content
to 10%. Vehicle controls were made by diluting DMSO with
water in a parallel fashion. A volume of 2 ml of each diluted
inhibitor solution was added to 2 ml of the culture medium
in separate wells of the culture plate; and equivalent
volumes of the corresponding vehicle controls were added to
the medium in a parallel set of wells. The final concentration
of DMSO for all groups was 0.01%. Cells were incubated at
378C for 1.5 h in 5% CO2. Cells were then washed with
PBS and collected by brief centrifugation. Cells were lysed
on ice for 15 min after adding 300 ml of ice-cold buffer con-
taining PBS, 1% Triton X-100 and a cocktail of protease
and phosphatase inhibitors (Roche). Cell lysates were centri-
fuged at 16 000g for 15 min at 48C and the supernatant was
collected for immediate use or storage at 2808C. Human
THP-1 monocyte cells were differentiated into macrophages
by treatment with 400 nM phorbol 12-myristate 13-acetate
for 24 h. THP-1 macrophage cells were then stimulated with
human interferon-gamma (100 ng/ml) for 48 h to induce ex-
pression of endogenous LRRK2 (18), followed by treatment
with LRRK2 kinase inhibitors as described earlier. Cleared
cell lysates from human lymphoblastoid cells and THP-1
macrophages were resolved on 7.5% SDS–PAGE gels and
transferred to PVDF membranes for western blot analysis of
LRRK2 phosphorylated at S935 (33) using a rabbit monoclo-
nal antibody against phospho-serine 935 LRRK2 (clone
UDD2, 1:6000; Epitomics). The blot was re-probed with a
mouse monoclonal antibody against LRRK2 amino acids
970–2527 (clone N241A/34, 1:15 000; NeuroMab) to detect
total LRRK2. Western blots were developed with enhanced
ECL reagents (Amersham) on X-ray films, which were
scanned into image files and analyzed for intensities of
protein bands using ImageJ.
LRRK2 immunostaining, cell toxicity and rescue assay
SH-SY5Y neuroblastoma cells were cultured in Opti-MEM
(Invitrogen) with 10% fetal bovine serum (FBS, Atlanta Bio-
logicals) and 1% penicillin (Invitrogen) and incubated in 5%
CO2 at 378C. One day prior to transfection, SH-SY5Y cells
were split and placed into six-well plates at a density of 3 ×
105/ml in 2 ml of medium per well. SH-SY5Y cells were
transfected with pCEP4 empty vector (Invitrogen), pCEP4
WT-LRRK2-FLAG and pCEP4 G2019S-LRRK2-FLAG
(34), all mixed with PCMV-GFP (Addgene) at 15:1 ratio.
The culture was changed to serum-free medium 1 h before
transfection and to complete medium 6 h post-transfection.
At 48 h post transfection, cells were fixed with freshly made
4% paraformaldehyde for 30 min. Cells were permealized
with phosphate-buffered saline (PBS) containing 0.2%
Triton X-100 on ice for 10 min and were blocked with 3%
BSA for 1 h at room temperature. Cells were then incubated
with 1:100 diluted rabbit mAb primary anti-LRRK2 (clone
UDD3, Epitomics) at 48C overnight, washed four times
(each for 15 min) in PBS and incubated with 1:300 diluted
Alexa Fluor488 goat anti-rabbit antibody for 2 h at room tem-
perature in the dark. Images were taken by using Zeiss Axio-
vert 200M microscope with 1.5 s exposure time at 20 or 40×
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magnifications. LRRK2 inhibitors and vehicle controls were
added to the cell medium from the start of transfection until
image collection. GFP positive cell images were captured
from 40 randomly selected fields 12 and 48 h post transfection.
Viable cells were quantified using Hoechst 33 342 stain added
to each well at 12 and 48 h post-transfection and images of 40
random fields for each well were captured using a fluorescence
microscope with the GFP and DAPI channels. GFP and corre-
sponding DAPI images were superimposed and GFP positive
viable cells were counted as having intact nuclei with dis-
persed chromatin versus total GFP positive cells.
Nematode strains and maintenance
Transgenic C. elegans lines expressing green fluorescent
protein (GFP) either alone or together with G2019S- or
R1441C-LRRK2 specifically in dopaminergic neurons using
the promoter of dopamine transport dat-1 have been described
previously (17). As all of the transgenic lines carry GFP as the
fluorescent marker for DA neurons, they were simply desig-
nated (with transgene specified in parentheses) as the GFP
only line (Pdat-1::GFP), G2019S line (Pdat-1::G2019S-
LRRK2; Pdat-1::GFP) and R1441C line (Pdat-1::R1441C-
LRRK2; Pdat-1::GFP), respectively. The A2016T inhibitor-resistant
mutation of LRRK2 (13) was introduced into pFXneEGFP
plasmid containing Pdat-1::R1441C (17) by site-directed mu-
tagenesis using QuikChange II XL kit (Stratagene), generating
a Pdat-1::R1441C/A2016T construct. The Pdat-1::G2019S/
A2016T construct was made by subcloning the insert from
pCMV-FLAG-LRRK2 G2019S/A2016T (13) into pFXneEGFP
plasmid containing Pdat-1 using BamHI and NotI sites. All
constructs were confirmed by DNA sequencing. For generat-
ing transgenic C. elegans lines expressing LRRK2 dual
mutant R1441C/A2016T or G2019S/A2016T in dopaminergic
neurons, young adult C. elegans hermaphrodites with
lin-15(765ts) allele (strain MT1898) were injected with a
mixture of DNA constructs consisting of Pdat-1::GFP
(20 ng/ml) together with Pdat-1::R1441C/A2016T or
Pdat-1::G2019S/A2016T (20 ng/ml), as well as lin-15+ selec-
tion marker (50 ng/ml; pJM23, a gift from L. Avery, Univer-
sity of Texas Southwestern Medical Center) and an empty
vector pSL1180 (20 ng/ml; Amersham). To construct dop-1/
R1441C C.elegans lines, a mixture of Pdat-1::R1441C
(20 ng/ul), Pdat-1::GFP (20 ng/ul) and an empty vector pBlue-
script (70 ng/ul) were injected into C. elegans with a dop-1
null allele (vs101). Stable extra-chromosomal transgenic
lines were selected based on the absence of the lin-15 Muv
phenotype and presence of both GFP marker and LRRK2
transgene, as previously described (17). Corresponding lines
with chromosomally integrated transgene were made by treat-
ment with UV and trimethyl psoralen, followed by backcross-
ing with the wild-type strain (N2 Bristol) for at least three
times. At least three C. elegans lines were characterized for
each genotype, and data from a representative line were pre-
sented. The CAT-2 overexpression line (Pdat-1::CAT-2;
Pdat-1::GFP, strain UA57, generated by G. Caldwell, Univer-
sity of Alabama) was obtained from the Caenorhabditis Gen-
etics Center (CGC). A list of C. elegans strains used in this
study is described in Supplementary Material, Table S3.
C. elegans strains were cultured on standard nematode
growth medium (NGM) agar plates seeded with E. coli
OP50 as a food source according to established protocols
(35). NGM was made with Bacto agar and Bacto peptone
from BD Biosciences and other chemicals from Sigma.
Mixed stage animals were maintained as bulk culture on
NGM agar at room temperature (228C). Prior to each experi-
ment, animals were age-synchronized by standard bleaching
and washing protocol to obtain embryos, from which develop-
mental stages were followed.
Behavioral assay
Well-fed worms with intact dopaminergic neural circuitry
move slower in the presence of bacterial food than in its
absence. This basal slowing response (or food-sensing re-
sponse) is solely controlled by endogenous dopamine levels
and was assayed as described (22). Briefly, food-containing
assay plates were prepared by spreading the bacterial food,
E. coli (OP50), in a ring on NGM agar, and together with non-
coated assay plates, were incubated at 378C overnight and
cooled to room temperature prior to assay. Age-synchronized
worms (about 10 worms of each strain) were transferred from
their food-containing culture plate to a non-food plate and
washed twice in S basal buffer (100 mM NaCl, 10 mg/ml chol-
esterol, 50 mM potassium phosphate, pH 6.0) to get rid of the
remaining food on their bodies. Worms were then transferred
to the food-containing or non-food assay plates prepared as
described earlier, settled for 5 min, and body bends in 20 s
intervals were recorded for each of the worms.
L-DOPA treatment
C. elegans to be tested was placed on NGM agar plates con-
taining 20 mM 3,4-dihydroxyphenylalanine (L-DOPA) for
6 h prior to assay for basal slowing response.
Neurodegeneration assay
Degeneration of dopamine (DA) neurons in live C. elegans
was analyzed essentially as described (36,37). Briefly, age-
synchronized worms were paralyzed by treatment with 3 mM
levamisole and mounted on glass slides. The DA neurons in
the head regions [four cephalic (CEP) neurons and two anter-
ior dierdic (ADE) neurons] were visualized for GFP fluores-
cence under a Zeiss Axiovert 200M microscope and
monitored at different ages (L4/adult Day 0 through Day 9).
The total numbers of CEPs and ADEs were scored for the
presence of intact neurons. DA neurons missing most of the
cell body and neurites were counted as degenerated. For
each strain, about 30 worms were analyzed in at least three in-
dependent experiments, with a total of 90–120 animals
scored in the same manner. The percent of intact neurons sur-
vived was calculated as number of intact ADE/CEP neurons
observed in all animals divided by total number of ADE/
CEP neurons expected if no degeneration occurred (six in
each animal times the number of animals tested), times 100.
Fluorescent images of DA neurons in the head region of
worms were taken with a Zeiss Axiovert 200M microscope
using 1 s exposure time at 20× magnification.
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Time course of worm treatment with LRRK2 inhibitors
Worm treatment with LRRK2 inhibitors was done in liquid
culture to achieve better drug exposure. For treatment of
C. elegans, stage L1–L4, with LRRK2 inhibitors, young
adult worms were age-synchronized by soaking in bleach
and sodium hydroxide to destroy worms but not eggs; the
resulting eggs were left in 1 ml M9 buffer [For 1 l: KH2PO4,
3 g; Na2HPO4, 6 g; NaCl, 5 g; MgSO4 (1 M), 1 ml] and
shaken at 100 r.p.m. at room temperature overnight to generate
synchronized L1 worms. The M9 buffer containing L1 worms
was distributed into 12-well plates together with E. coli OP50
to make a total volume of 900 ml (300 ml M9 + 600 ml OP50)
in each well. Each well contained roughly 100 L1 worms.
LRRK2 inhibitors were added to achieve the desired concen-
trations. The 12-well plates were maintained in a water
chamber at room temperature and shaken at 100 r.p.m.
Worms were monitored every day and placed onto agar
plates with OP50 when most of them reached L4 stage,
according to morphological assessment (roughly 60 h). L4
worms were picked, settled in agar plates with OP50 for
48 h and tested by the behavioral assay as described earlier.
For treatment of worms at stage L4 to Day 2 with LRRK2
inhibitors, synchronized L1 worms were left growing on
agar plates with OP50 until reaching L4 stage. L4 worms
were washed with M9 buffer and distributed into 12-well
plates together with OP50 and LRRK2 inhibitors (each well
contained 50 worms). The plates were left in a water
chamber at room temperature (22oC) and shaken at
100 r.p.m. for 48 h and then the worms were transferred
onto agar plates with OP50 and settled for 24 h for the food
sensing test. For treatment from adult Day 2 to Day 3 and
Day 5 to Day 7, synchronized worms at Day 2 and Day 5
were treated essentially the same as for L4 to Day 2 treatment,
except Day 2 to Day 3 treatment only lasted 24 h in liquid
culture.
6-OHDA treatment
For testing whether the LRRK2 inhibitors afforded protection
from 6-OHDA-induced DA neuron death in C. elegans, syn-
chronized L1 Pdat-1::GFP worms were treated in liquid
culture for 36 h with LRRK2 inhibitors, or vehicle control,
as described earlier until they reached the L3 stage. The L3
worms were collected into 1.5 ml tubes and centrifuged at
1000 r.p.m. to remove supernatant. Five hundred microliters
of 50 mM 6-OHDA and 10 mM ascorbic acid were added to
each tube and mixed gently every 15 min for 1 h at room tem-
perature (228C). The worms were then washed with M9 three
times and re-placed into liquid culture with E. coli OP50 and
LRRK2 inhibitors for another 24 h. After that, worms were
transferred onto agar plates with OP50 for monitoring DA
neuron death.
Worm protein extraction, affinity pull-down and western
blotting
Five 10 cm NGM plates full of adult transgenic worms expres-
sing Flag-tagged G2019S- or R1441C-LRRK2 were used to
obtain eggs by alkaline bleaching and subsequently age-
synchronized L1 larva. Worms were grown in liquid culture
until L4 stage, harvested and homogenized in ice-cold lysis
buffer containing 0.5% Triton X-100 in 20 mM Tris, pH 7.5
supplemented with protease inhibitors (Roche). Total lysates
were clarified by centrifugation at 16 000g for 15 min at
48C. Affinity pull-down of Flag-tagged LRRK2 proteins was
achieved by incubation of 20 mg lysate proteins with anti-Flag
M2 mAb conjugated beads (Sigma). The beads were washed
in lysis buffer and bound proteins were eluted with 2× SDS
sample buffer heated at 958C. Proteins were separated on
7.5% SDS–PAGE gels and western blotting was performed
using anti-LRRK2 rabbit mAb (Epitomics, clone MJFF-2).
An aliquot of lysate was analyzed by western blotting as an
input control using anti-tubulin mouse mAb E7 (Developmen-
tal Studies Hybridoma Bank).
RT–PCR and quantitative PCR (qPCR)
Age-synchronized adult transgenic worms expressing GFP,
G2019S-LRRK2 and R1441C-LRRK2 were picked individu-
ally into PCR tubes (one worm per tube) and washed twice
in water. RNA was extracted from each worm using PicoPure
RNA Isolation Kit (Invitrogen), followed by DNase treatment
according to the manufacturer’s instructions. First strand
cDNA was synthesized from RNA using SuperScript II
Reverse Transcriptase (Invitrogen). One-tenth of the synthe-
sized cDNA was used as template for conventional PCR
with primers specific to LRRK2 and an internal reference
gene act-1 to amplify unique products for visualization on
agarose gel. Another aliquot of cDNA was used as template
for quantitative real-time PCR reactions with Fast SYBR
Green Master Mix and appropriate primers using StepOne
qPCR system (Applied Biosystems). The cycling was per-
formed at 958C for 5 min, followed by 40 cycles at 958C for
15 s and at 608C for 1 min. Data were processed with
StepOne software and analyzed using the comparative cycle
threshold method. Relative LRRK2 mRNA levels in individ-
ual worms were calculated as the values normalized to the in-
ternal control gene act-1. Primer sequences (5′ to 3′) specific
for human LRRK2 and worm act-1 genes were listed as
follows:
† LRRK2: forward-TTT GCT GGT TCC AAG CAG TT,
reverse-ACA TTC TGT TTG GGC GAA GT;
† act-1: forward-GCT GGA CGT GAT CTT ACT GAT
TAC C, reverse-GTA GCA GAG CTT CTC CTT GAT
GTC
Worm lifespan assay
Worms were treated with different concentrations of inhibitors
for the L1–L4 duration in liquid culture and then transferred
to OP50 agar plates and settled for 24 h. Fifteen post L4,
Day 1 worms were transferred into one OP50 agar plate
with 1.25 mg/ml 5-fluorodeoxyuridine. The worms were
monitored every day until all worms were dead in each
plate. The life span curves were generated by plotting percent-
age of surviving worms at each time point. Percent surviving
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was determined by scoring 10 plates of worms at each inhibi-
tor concentration.
Statistics
Data were presented as mean+SEM. Statistical significance
of differences between results was analyzed using the Stu-
dent’s t-test for single comparisons or one-way ANOVA fol-
lowed by the Turkey–Kramer post hoc test for multiple
comparisons. A P-value ,0.05 was considered significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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